Brain tumor treatment inconsistent in US and Canada
|
Tweet
|
|
Patients who develop the most common kind of primary malignant brain tumor are sometimes given drugs they may not need and deprived of others that might help, medical researchers said on Tuesday.
Primary brain tumors are those that originate in the brain, rather than being spread there by cancer elsewhere in the body. Survival rates for those diagnosed with the more serious forms of the tumors, malignant glioma, run three to five years to as little as one year in the worst cases.
Researchers at the University of California in San Francisco said a look at 788 adult patients treated at 52 U.S. and Canadian sites from 1997 to 2000 found that treatment varied greatly and was sometimes in conflict with guidelines.
Their study said the use of diagnostic tools and treatments such as magnetic resonance imaging, radiation and surgery were consistent.
But it also found that fewer than 70 percent of patients were given chemotherapy, even though research indicates it is useful for brain tumors. In addition 89 percent in the study were given anticonvulsant drugs, even though only 31 percent had problems with seizures.
“While it is accepted that patients who present with seizures should receive anti-epileptic drugs, there is strong evidence that prophylactic (uses) have little value for seizure-free patients with newly diagnosed brain tumors,” the report said.
Such drugs “are associated with significant side effects” and should be discontinued the first week after surgery if no seizure problems develop, it added.
“Our goal in neuro-oncology is to improve the duration and quality of survival of our patients,” said Susan Chang, a physician at the school who led the research.
Brain tumor specialists need to communicate with each other but also should collaborate with “other health care providers, including emergency physicians, primary physicians, neurologists and oncologists...so that the optimum care is provided,” she said.
The report, appearing in this week’s issue of The Journal of the American Medical Association, was supported in part by grants from Aventis Pharma Ltd., part of Sanofi-Aventis, and Guilford Pharmaceuticals Inc., as well as the National Institutes of Health.
Revision date: July 5, 2011
Last revised: by Janet A. Staessen, MD, PhD
| RELATED STORIES: | ||
| Comments | [ + Post Your Own ] |
Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.
There are no comments for this entry yet. [ + Comment here + ]
We are pleased to let readers post comments about an article. Please increase the credibility of your post by including your full name and email.
All comments are reviewed by our editors before they are posted on the site. Just keep it clean, kids.
- Full Story - - »»»
Best time for a coffee break? There’s an app for that
- Full Story - - »»»
Cellphone Use Linked to Selfish Behavior in UMD Study
- Full Story - - »»»
Optimism about heart risks may be a good thing
- Full Story - - »»»
New guidelines developed for improved DVT diagnosis
- Full Story - - »»»
Teen pregnancy, abortion rates at record low, study says
- Full Story - - »»»
Think you can’t get pregnant? Try again, study says
- Full Story - - »»»

